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A highly reproducible quantitative 
viral outgrowth assay for the 
measurement of the replication-
competent latent HIV-1 reservoir
Axel Fun, Hoi Ping Mok, Mark R. Wills* & Andrew M. Lever*
Cure of Human Immunodeficiency Virus (HIV) infection remains elusive due to the persistence of HIV in a 
latent reservoir. Strategies to eradicate latent infection can only be evaluated with robust, sensitive and 
specific assays to quantitate reactivatable latent virus. We have taken the standard peripheral blood 
mononuclear cell (PBMC) based viral outgrowth methodology and from it created a logistically simpler 
and more highly reproducible assay to quantify replication-competent latent HIV in resting CD4+ T 
cells, both increasing accuracy and decreasing cost and labour. Purification of resting CD4+ T cells from 
whole PBMC is expedited and achieved in 3 hours, less than half the time of conventional protocols. 
Our indicator cell line, SupT1-CCR5 cells (a clonal cell line expressing CD4, CXCR4 and CCR5) provides a 
readily available standardised readout. Reproducibility compares favourably to other published assays 
but with reduced cost, labour and assay heterogeneity without compromising sensitivity.
Over the last two decades advances in antiretroviral therapy (ART) have transformed infection with Human 
Immunodeficiency Virus (HIV) from a lethal disease into a manageable chronic condition for the majority of 
patients with access to high-quality treatment1. Despite this success, patients must adhere to life-long therapy 
since cessation of treatment inevitably results in rebound of plasma viraemia and restitution of disease progres-
sion2–5. The predominant source of recrudescent virus is reactivation from a stable reservoir of latently HIV 
infected resting CD4+ T cells which is unaffected by ART and as such prevents eradication of HIV6,7. Current 
efforts to cure HIV infection or to achieve therapy-free remission aim at depleting or, preferably, eradicating this 
latent population8.
Accurate quantitation of the latent viral load is critical for the evaluation of these cure strategies. Whilst the 
bulk of resting CD4+ T cells reside in tissues, the latent HIV reservoir is usually measured in peripheral blood 
resting CD4+ T cells for reasons of accessibility. In these long-lived cells HIV persists as integrated proviruses 
giving the latent HIV population an estimated half-life of 44 months9. A variety of techniques are used to quanti-
tate latent HIV including PCR based assays for total HIV and integrated proviral DNA, ultrasensitive single-copy 
RNA assays, inducible multiply-spliced HIV RNA and culture-based viral outgrowth assays10–14. Most proviruses 
are defective and there is poor correlation between these assays15. There is no agreement as to which assay approx-
imates best to a biologically meaningful measure of the latent viral load10. However, the consensus opinion is that 
the quantitative viral outgrowth assay, which determines the size of the replication-competent, inducible proviral 
reservoir in resting CD4+ T cells, represents a definitive minimal estimate of its ‘true’ size and is clinically relevant 
for recrudescence and disease progression15,16.
The standard quantitative viral outgrowth assay measures replication-competent latent HIV by co-cultivation 
of ex vivo activated resting CD4+ cells with PBMCs from HIV negative donors13. Although this is a powerful 
methodology, it has some major drawbacks. The assay is laborious, time consuming and expensive. Heterogeneity 
of expression of CCR5 on cells from different seronegative donors affects the sensitivity of the assay. These factors 
combine to make the standard viral outgrowth assay unwieldy for studies with large sample numbers. In clinical 
trials that compare samples at multiple time-points, as occurs in many of the current eradication studies, assay 
reproducibility is essential17.
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We report a streamlined viral outgrowth assay that uses a dual co-receptor expressing cell line, SupT1-CCR5, 
to replace the PBMC co-culture and employs a single-step resting CD4+ T cell purification from peripheral blood 
with a custom antibody cocktail. These modifications significantly reduce labour and cost and improve assay 
stability. Our quantitative viral outgrowth assay is easy to perform, robust, relatively inexpensive and can be used 
for small studies in labs with limited experience with outgrowth assays, or for large scale studies, without the need 
for extensive human resources.
Results
Rapid purification of resting CD4+ T cells from whole blood. The highly purified resting CD4+ T 
cells required for the viral outgrowth assay are conventionally obtained in three steps: 1) isolation of PBMCs 
from whole blood using density gradient centrifugation, 2) negative selection from PBMCs to enrich for total 
CD4+ T cells using a commercially available antibody cocktail followed by 3) depletion of activated CD4+ T cells, 
commonly by targeting cell-surface activation markers CD25, CD69 and HLA-DR. Latently infected cells are rare 
thus typically large blood volumes are required for the viral outgrowth assay and isolation of resting CD4+ T cells 
generally requires 6–8 hours.
To expedite this process we used SepMate-50 tubes for the isolation of PBMCs from whole blood. They permit 
easier layering of the blood:PBS mixture onto the density medium and allow for shorter centrifugation times at 
higher speeds with use of the centrifuge brakes, cutting processing time by as much as 2 hours. The two-step pro-
cedure for purifying resting CD4+ T cells from PBMCs is widely used because there are as yet no commercially 
available kits for the selection of resting CD4+ T cells. Negative selection kits for total CD4+ T cells are availa-
ble from several manufacturers and depletion of activated cells can be achieved in various ways such as direct 
removal using anti-CD25/CD69/HLA-DR coated beads or staining for these markers and subsequent depletion 
using beads targeting the conjugated fluorophore. We depleted activated CD4+ T cells using FITC conjugated 
antibodies against these three markers and removed them with anti-FITC magnetic beads. Alternatively, we iso-
lated highly purified resting CD4+ T cells using a custom antibody cocktail which consisted of a CD4+ T cell 
isolation kit supplemented with anti-CD25/CD69/HLA-DR.
The efficacy of both purification methods was tested on PBMCs that were isolated from an apheresis cone 
and stimulated for 3 days with 10 U/ml Interleukin-2 (IL-2) and 1 μ g/ml Phytohaemagglutinin - Leucoagglutinin 
(PHA-L). This resulted in expression of CD25 and CD69 on > 50% of CD4+ T cells and HLA-DR on > 3% of 
CD4+ T cells, levels far higher than usually observed in clinical samples (ranges in our patient cohort: CD25 
0.4–16.8%; CD69 0.2–1.5%; HLA-DR 0.5–11%). Equal amounts of activated PBMCs were then processed using 
either the two-step or one-step protocol. Even under these unphysiological conditions, both methods resulted in 
highly purified resting CD4+ T cells (Supplementary Figure 1).
When tested on clinical samples, both procedures yielded equally pure populations of resting CD4+ T cells 
(Fig. 1) with similar recovery rates while the one-step protocol reduced processing time from roughly 2 hours to 
45 minutes. The conventional two-step procedure resulted in an average purity (± standard deviation) of 97.8% 
(± 1.6%) resting CD4+ T cells (n = 20, range 93.5–99.7%) and the one-step procedure using the custom antibody 
kit returned an average purity of 98.5% (± 1.1%) resting CD4+ T cells (n = 14, range 96.1–99.5%). There was no 
statically significant difference between the two purification methods (p = 0.12, Mann-Whitney test). With this 
new method, highly purified resting CD4+ T cells could be obtained from whole blood in no more than 3 hours.
Virus released from infected CD4+ T cells replicates more efficiently in SupT1-CCR5 cells com-
pared to CD8-depleted seronegative donor PBMCs. We compared the ability of SupT1-CCR5 cells 
with that of CD8-depleted PBMCs from seronegative donors to amplify virus released from infected primary 
CD4+ cells by co-culturing each with serial dilutions of infected CD4+ T cells. SupT1-CCR5 cells are SupT1 
cells which endogenously express CD4 and CXCR4 and were engineered to stably express CCR5. Primary CD4+ 
T cells were isolated from a single donor and infected with either laboratory strain LAI (X4-tropic virus), BaL 
(R5-tropic) or clinical isolate MCV (R5-tropic). After 21 days of co-culture viral replication was assayed in each 
individual well by p24 ELISA.
SupT1-CCR5 cells were able to amplify LAI virus released from 10 fold fewer infected cells than were donor 
#1 and #2 CD8-depleted PBMCs and half that of donor #3 CD8-depleted PBMCs (Fig. 2). They also amplified 
virus released from BaL infected cells more efficiently and required 5 fold fewer infected cells than donor #1 and 
#2 PBMCs. Emphasising the heterogeneity of PBMCs as an amplifying cell population, the CD8-depleted PBMCs 
from donor #3 were not able to amplify virus from BaL infected cells in this experiment. In contrast, these cells 
were superior in amplifying virus from MCV infected cells, requiring 5 fold fewer infected cells to become p24 
positive than SupT1-CCR5 and donor #2 cells. CD8-depleted PBMCs from donor #1 required twice the number 
of infected cells to become positive compared to SupT1-CCR5 and donor #1 cells and 10 times more than donor 
#3 CD8-depleted PBMCs.
The inconsistent replication efficiency of the two different R5-tropic viruses seen with donor #3 CD8-depleted 
PBMCs demonstrates the capricious ability of donor derived PBMCs to support viral replication when using 
unselected seronegative donors. By contrast, SupT1-CCR5 cells were excellent amplifier cells, better able to sup-
port viral replication and performed more uniformly than CD8-depleted PBMCs from unmatched, unscreened 
healthy donors.
SupT1-CCR5 cells are as efficient as CD8-depleted seronegative donor PBMCs at amplify-
ing reactivated virus in the viral outgrowth assay. A drawback of the conventional PBMC based 
co-culture assay is the heterogeneity of CCR5 expression on donor PBMCs. Using PBMCs from healthy donors 
that exhibit high levels of CCR5 expression after mitogen stimulation can greatly enhance the sensitivity of the 
PBMC co-culture based outgrowth assay18. Therefore it is common practice to screen for donors with high levels 
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of CCR5 expression or even use matched patient-donor pairs in the standard PBMC co-culture assay17. While 
this may improve the sensitivity of the assay it also increases time, labour, complexity and cost of each assay. 
Using individual matched donors also prevents inter assay benchmarking between different donor-patient pairs. 
Figure 1. The custom antibody kit yields highly purified resting CD4+ T cells. (a) Resting CD4+ T cells 
obtained with the one-step protocol (middle panel) or total CD4+ T cells with the two-step protocol (right 
panel) were stained with anti-CD3-PerCP/Cy5.5 and anti-CD4-FITC and their purity was analysed by flow 
cytometry. Both methods yielded equally pure CD4+ T cell populations. (b) To test if activated CD4+ T 
cells were efficiently depleted by the custom antibody kit, isolated cells were stained with anti-CD4-FITC, 
anti-CD25-PE/Cy7, anti-CD69-Pacific Blue and anti-HLA-DR-APC and their purity was analysed by flow 
cytometry. No activated cell contamination was observed.
Figure 2. Ability of different amplifier cells to support viral replication of virus released from infected 
cells. Serial dilutions of infected CD4+ T cells (supplemented to a total of 500000 CD4+ T cells with uninfected 
CD4+ T cells) were co-cultured with 5 × 105 SupT1-CCR5 cells or 1.34 × 106 CD8-depleted PBMCs from 
three unselected healthy donors. After 21 days of co-culture mimicking assay conditions, viral production was 
measured by HIV p24 ELISA. Results were normalised to the lowest number of infected cells that sustained 
viral replication in SupT1-CCR5 cells. A reading higher than 1 indicates the donor PBMCs were able to amplify 
virus from fewer infected cells than the SupT1-CCR5 cells and a reading lower than 1 that they required more 
infected input cells than SupT1-CCR5 cells. (ND - not detected). No viral replication was detected for donor 3 
at the highest concentration of BaL infected cells.
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Replacing the CD8-depleted healthy donor PBMCs that have to be added to the assay on days 2, 9 and 16 with 
a cell line stably expressing CD4, CXCR4 and CCR5 that only requires a single addition on day 2 could increase 
sensitivity, inter-assay homogeneity and substantially reduce labour and cost of each assay.
To evaluate the SupT1-CCR5 based viral outgrowth assay, resting CD4+ T cells were isolated from viro-
logically suppressed HIV-1 positive individuals and divided equally for parallel outgrowth assays using either 
SupT1-CCR5 cells or CD8-depleted healthy donor PBMCs. Six samples from five patients (one patient was 
assayed twice) were used for direct comparisons (Fig. 3). The healthy donor PBMCs for each assay were from six 
different donors obtained from the NHS Blood and Transplant Centre. In all samples replication competent virus 
was detected using both SupT1-CCR5 cells and healthy donor PBMCs. In 4/6 samples SupT1-CCR5 cells gave 
a higher frequency of latently infected cells, reported as infectious units per million cells (IUPM) and in 2/6 the 
PBMC co-cultures resulted in a higher IUPM (Fig. 3a). There was no statistically significant difference in IUPM 
between the SupT1-CCR5 cell viral outgrowth assay and the standard PBMC co-culture assay (Fig. 3b).
The SupT1-CCR5 based viral outgrowth assay shows a high level of reproducibility. To evaluate 
the reproducibility of the SupT1-CCR5 based viral outgrowth assay we determined the IUPM in two HIV positive 
individuals at multiple time-points. Both patients were undergoing regular venesection for the coincidental treat-
ment of haemochromatosis. We tested 8 samples over 4 months from one patient (P16, Table 1). This patient was 
virologically suppressed and no HIV RNA blips were reported over this period. In addition, we tested 3 samples 
taken over 19 months from a second patient (P6, Table 1). The patient was virologically suppressed throughout 
this period. All 8 samples from P16 had an IUPM between 1.240 and 1.701 indicating very high assay reproduc-
ibility with a standard deviation of only 0.17 (95% confidence interval (CI) 0.11–0.34) (Fig. 4). The 3 samples 
from P6 which were taken at months 0, 3 and 19 were consistently negative suggesting a very small inducible 
replication-competent latent reservoir size of < 0.052 IUPM which was at the lower limit of detection for the assay 
with an input of 1.92 × 107 resting CD4+ T cells19.
Measurement of the replication-competent latent reservoir in a heterogeneous patient cohort 
by the SupT1-CCR5 based viral outgrowth assay. To evaluate the performance of the assay in a clinical 
setting 25 patients were recruited. Of these patients 20 were stably suppressed and 5 were viraemic. The baseline 
characteristics of these patients are listed in Table 1.
The heterogeneity of the cohort and variations in the amount of blood drawn resulted in a broad range of rest-
ing CD4+ T cell recovery with an average of 3.59 × 107 cells obtained (range 1.2 × 107–108). Replication-competent 
virus was detected in 21/25 patients with a median latent reservoir size of 0.417 IUPM. Consistent with pub-
lished data, viraemic patients had a larger reactivatable HIV population than virologically suppressed patients 
(Fig. 5)14,20,21. The size of the latent reservoir (log transformed IUPM) in suppressed patients inversely correlated 
with time of virological suppression (< 400 copies/ml) (n = 12, Spearman r = − 0.8947, p < 0.001), concordant 
with the current understanding of early establishment and slow decay of the latent HIV pool20,22–26. There was 
also a clear trend supporting an inverse correlation between the size of the latent reservoir (log10 IUPM) and time 
on treatment (n = 16, Spearman r = − 0.4676, p = 0.0678) and virological suppression < 50 copies/ml (n = 12, 
Spearman r = − 0.3193, p = 0.3117). Although these did not reach statistical significance, this was probably due 
to the small data set and the virological suppression (< 50 copies/ml) data was possibly confounded by viral blips.
SupT1-CCR5 cells readily form syncytia during HIV-1 infection (Fig. 6a). We speculated whether the cyto-
pathic effect (CPE) could be used as an alternative read-out to the p24 ELISA. Detailed observation was made 
of CPE from 18/25 assays and an IUPM was calculated for each based on the number of positive wells scored by 
Figure 3. Direct comparison of the SupT1-CCR5 cell based assay with the ‘standard’ PBMC based assay. (a) 
Purified resting CD4+ T cells were split in half and parallel assays run with SupT1-CCR5 cells (blue bars) and 
CD8-depleted PBMCs as amplifier cells (red bars). PBMCs were from unselected seronegative donors. Patient 
identifiers are depicted on the X-axis, P16.7 and P16.8 were samples from the same patient taken at different 
time points. Error bars indicate the 95% confidence interval (CI) for each individual assay. (b) There was no 
statistically significant difference in IUPM values between the two types of amplifier cells. Colours indicate the 
corresponding samples from the same patient and are connected by a coloured line. Horizontal bars represent 
the geometric mean of each data set and the error bars indicate the 95% CI. P-value was calculated using a 
Wilcoxon matched pairs test.
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Pt. ID Age (years) Sex
Time since 
diagnosis 
(years)
Nadir 
CD4 count 
(cells/mm3)
CD4 count at 
sample time 
(cells/mm3)
VL at 
sample 
time (c/ml)
Time 
on ARV 
(months)
Time 
VL < 50 c/ml 
(months)
Time 
VL < 400 c/ml 
(months)
Therapy 
regimen 
(current)
Recovered 
resting CD4 
cells (×106) IUPM
P1 42 F 10 N/A 450 < 50 114 N/A N/A N/A 42 0.193
P2 48 M 23 N/A 350 < 50 234 N/A N/A N/A 65 0.350
P3 48 F 9 N/A 530 < 50 102 N/A N/A N/A 65 0.220
P4 63 M 7 300 820 < 50 63 57 73 TDF, FTC, DRV/r 22 neg
P5 51 M 27 N/A 980 < 50 270 > 123 > 123 TDF, FTC, RAL, DRV/r 50 0.049
P6 66 M 12 140 470* < 50 143 143 143 ddI, 3TC, EFV 19* neg
P7 52 F 16 110 420 < 50 180 171 171 ABC, 3TC, NVP 40 0.048
P8 57 M 4 270 580 < 50 55 55 56 TDF, FTC, ATV/r 22 neg
P9 53 M 20 360 640 < 50 92 42 167 TDF, FTC, DRV/r 29 0.046
P10 73 M 9 370 460 < 50 92 49 111 TDF, FTC, DRV/r 39 0.063
P11 50 F 20 N/A 740 < 50 242 > 78 > 78 d4T, ddI, DRV/r 34 0.567
P12 57 M 10 9 370 < 50 124 124 124 TDF, FTC, EFV 17 0.215
P13 54 F 14 170 > 1500 < 50 167 42 173 TDF, FTC, EFV 100 0.046
P14 58 M 12 280 430 < 50 150 > 75 > 75 ABC, 3TC, EFV 21 neg
P15 62 F 6 160 520 < 50 68 24 68 TDF, FTC, NVP 22 1.062
P16 61 M 8 30 440* < 50 91 28 70 TDF, FTC, ATV/r 27* 1.594*
P17 55 M 6 320 650 < 50 70 65 75 TDF, FTC, EFV 66 0.775
P18 46 M 11 220 850 < 50 133 59 86 ddI, 3TC, ATV/r, RAL 80 0.417
P19 48 F 11 N/A 1070 < 50 28 N/A N/A TDF, FTC, EFV 32 0.516
P20 47 M 4 90 320 < 50 42 5 41 TDF, FTC, ATV/r 25 0.479
VP1 42 M 11 N/A 480 4,538 none viraemic viraemic Therapy naïve 20 0.933
VP2 37 M 3 410 570 76,193 none viraemic viraemic Off therapy 20 0.051
VP3 40 M 4 N/A 390 134,535 none viraemic viraemic Therapy naïve 12 117
VP4 45 F 6 N/A 370 6,892 none viraemic viraemic Off therapy 12 24.848
VP5 51 M 3 230 N/A 8,000 none viraemic viraemic Off therapy 16 4.574
Table 1.  Patient characteristics. P - suppressed patient; VP - viraemic patient; N/A - data not available; 
ARV - antiretroviral therapy; VL – viral load; c/ml – copies/ml; IUPM - infectious units per million cells; neg 
- negative result (no replication-competent HIV detected). *Average of multiple samples from a single patient. 
Antiretroviral drugs: TDF - tenofovir disoproxil fumarate; FTC - emtricitabine; DRV/r - darunavir boosted 
with ritonavir; RAL - raltegravir; ddI - didanosine; 3TC - lamivudine; EFV - efavirenz; ABC - abacavir; NVP - 
nevirapine; ATV/r - atazanavir boosted with ritonavir; d4T - stavudine.
Figure 4. The SupT1-CCR5 cell based viral outgrowth assay has excellent reproducibility. Blood was 
collected from a patient undergoing regular venesection for the treatment of haemochromatosis (P16, Table 1). 
SupT1-CCR5 cell-based viral outgrowth assays were performed on a set of 8 blood samples from this patient to 
assess the reproducibility of the assay. The date of venesection is depicted on the X-axis with the first sample set 
as week 0.
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this method. CPE results showed a near exact correlation with the p24 results (Pearson’s correlation coefficient, 
r = 0.9998) (Fig. 6b). From several CPE positive wells viral RNA was isolated and sequenced and all viruses tested 
had an R5-tropic genotype (http://coreceptor.geno2pheno.org/) indicating that the SupT1-CCR5 cells readily 
sustain infection with R5-tropic virus and form syncytia in a similar manner to infection with X4-tropic virus. All 
viruses tested to date induce syncytia formation in these cells. The wide variety of viruses tested include labora-
tory reference viruses LAI, NL4-3 (X4-tropic), BaL (R5-tropic), HIV-2 (SVR clone, induces smaller syncytia than 
the HIV-1 strains but was clearly discernible) and > 30 clinical isolates. In the 18 assays with comprehensive CPE 
Figure 5. Size of the replication-competent latent HIV reservoir as determined by the SupT1-CCR5 cell 
based viral outgrowth assay. The assay was tested on a cohort of 25 patients, 20 of whom were virologically 
suppressed and 5 untreated patients (Table 1). Viraemic patients had a statistically significant larger latent HIV 
reservoir than aviraemic patients. Horizontal bars represent the geometric mean of each data set. LoD indicates 
the limit of detection. The samples indicated in red were negative and therefore have an IUPM < 0.046–0.052, 
the LoD of the assay with the number of input cells used in these four assays. P-value was calculated using a 
Mann-Whitney test.
Figure 6. SupT1-CCR5 cells induce syncytia formation upon HIV infection. (a) During culture, SupT1-
CCR5 cells cluster together in clumps. Mixing the cells disrupts the clumps and creates a single cell suspension 
which can aid the detection of syncytia. The different stages of progressive infection from non-infected cells to 
widespread CPE in a SupT1-CCR5 culture infected with HIV from reactivated patient-derived CD4+ T cells. 
The black arrows in the Stage 1 panel point the first appearances of syncytia in the culture. (b) Correlation 
between p24 and CPE read-out. From 18/25 assays comprehensive CPE data was available. The number of 
positive wells scored by observation of syncytia was converted into an IUPM for each assay and compared to the 
IUPM based on p24 production. There was a strong correlation between the two read-out methods (Pearson’s 
correlation coefficient, r = 0.9998).
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data available, the start of syncytia formation was generally observed around the earliest time p24 was measurable 
in a well, suggesting that both methods have similar sensitivities. Thus visual scoring of CPE could be used as a 
reliable corroborative or alternative read-out for all viral isolates.
Discussion
Developments in HIV latency research and latency reversal have led to a renewed interest in clinical studies 
aimed at virus eradication and have dramatically increased the use and importance of accurate quantitative viral 
outgrowth assays. The current standard assay requires leukapheresis or a very large blood draw to obtain sufficient 
resting CD4+ T cells. CD8-depleted HIV negative donor PBMCs must be prepared at least twice, either freshly 
isolated, or thawed and subsequently stimulated, to maximise permissiveness for HIV infection at least 2 days 
prior to the day they are needed. The cost of a single assay can therefore amount to several thousands of dollars in 
consumables alone. Expression levels of CCR5 on HIV negative donor cells vary significantly between individuals 
and it has been shown that using donors that express high levels of CCR5 greatly enhances the sensitivity of the 
assay18. This has led to screening for donors with high levels of CCR5 expression or using matched patient-donor 
pairs exhibiting optimal viral replication. This involves extensive pre-screening adding further to the complexity 
and cost of the assay. Matched patient-donor pairing also inhibits standardisation between assays and laborato-
ries. Such factors make the assay prohibitive for laboratories with limited resources or for use in large studies with 
a high sample number.
We have updated and streamlined the quantitative outgrowth assay to reduce cost and labour while main-
taining sensitivity and improving reproducibility. A single individual can perform and maintain multiple assays 
simultaneously. By using specialised tubes for density gradient PBMC isolation and replacing the two-step resting 
CD4+ T cell isolation by a single-step procedure, the processing time from whole blood to highly purified resting 
CD4+ T cells is reduced from 6–8 to only 3 hours. Substituting the seronegative donor PBMC co-culture with a 
cell line based co-culture that only requires a single addition of cells on day 2 significantly decreases labour and 
cost and increases manageability. Read-out for positive wells is flexible and can be adjusted to the user’s require-
ments. We opted for p24 ELISA as it is simple, robust and cheap. PCR-based techniques can be a more sensitive 
alternative and may allow for a shorter co-culture time14. The system also offers an alternative option to further 
reduce labour and cost by visual observation of syncytia formation. We show that CPE data correlate closely with 
the p24 read-out.
Assay reproducibility is paramount in the clinical trial setting. After statistical analysis of 160 standard assays 
using matched patient-donor pairs on samples from 37 patients, Crooks et al. reported the standard deviation of 
log transformed latent viral load (log10 IUPM) to be 0.38 and calculated a > 6-fold decrease as a reliable parameter 
to identify an effect of the intervention17. Expressed as log10 IUPM, our unique reproducibility data on multi-
ple samples at short intervals from the same patient shows a standard deviation of only 0.049 (95% CI 0.032–
0.100), suggesting our assay is capable of detecting even smaller changes in the replication-competent latent HIV 
reservoir.
Alternative published approaches have also sought to simplify and shorten the gold standard viral outgrowth 
assay. One measures the frequency of cells with inducible multiply-spliced HIV RNA (TILDA)11 and another 
uses a viral outgrowth assay that replaces the required seronegative donor PBMCs with a cell line (MOLT-4/
CCR5)14. While TILDA is very rapid (2 days) and requires less than a million input cells, it detects cells that have 
inducible multiply-spliced HIV RNA but cannot distinguish if these cells produce the more biologically relevant 
replication-competent virus. It also samples the total CD4+ T cell pool, a very different population than the 
resting CD4+ T cells used in quantitative viral outgrowth assays, exemplified by a median frequency of infected 
cells 48 times higher than measured by a quantitative viral outgrowth assay11. The MOLT-4/CCR5 based viral 
outgrowth assay uses an RT-PCR targeted at polyadenylated HIV RNA to detect virus production14. While PCR 
is more sensitive than a p24 ELISA, it is more complex and expensive and in contrast to SupT1-CCR5 cells, the 
MOLT-4/CCR5 cells express CCR5 under the control of the G418 selectable marker. G418 inhibits polypep-
tide synthesis and the effect on patient-derived CD4+ T cells and virus production from reactivated cells is not 
known, although it is not reported to influence the assay. As the MOLT-4/CCR5 cells are also described as highly 
susceptible to HIV14 they are a plausible alternative reporter line for the SupT1-CCR5 cells. Similar to other 
versions of the quantitative outgrowth assay, our assay represents a minimal estimate of the size of the inducible 
replication-competent latent HIV reservoir. Not all latently infected cells are induced to produce virus upon a 
single round of stimulation. Negative wells that received an additional round of PHA stimulation occasionally 
became positive whereas their paired counterparts that did not receive additional stimulation remained negative 
(data not shown), similar as described by Ho et al.16.
Our quantitative viral outgrowth assay is simple, manageable, highly reproducible and cost-effective. 
Processing time to obtain highly purified resting CD4+ T cells from whole blood is reduced compared to other 
viral outgrowth assays and is achievable within 3 hours. It requires a single addition of amplifier cells on day 2 and 
no selective medium. Including the p24 ELISA, the cost of a single assay is < £600 (GBP) and can be substantially 
lower if scaled up for multiple assays. The manageability and relatively low assay cost make it more accessible for 
limited resource settings or for larger scale studies requiring a large number of samples to be processed.
Materials and Methods
Patient cohort and blood draws. All participants gave written informed consent and this study was 
approved by the National Health Services (NHS) Health Research Authority (UK) under REC reference 12/
SC/0679. All experimental procedures were approved by the institutional review board of the University of 
Cambridge and were performed in accordance with the relevant guidelines.
Twenty-five patients were included in the study of whom 20 were aviraemic and 5 had detectable plasma 
HIV-1 RNA (Table 1). The average age of the cohort was 52.2 (median 51, range 37–73) years and consisted of 17 
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(68%) men and 8 (32%) women. From the majority of patients (20/25) blood was drawn using standard needles 
and syringes and transferred to 50 ml tubes containing 5 ml 100 U/ml heparin as anticoagulant (volume collected: 
125–200 ml, median 170 ml). From 5/25 blood was collected using a blood collection bag containing citrate phos-
phate dextrose adenine solution (CPDA-1) as anticoagulant (volume collected: 300–600 ml). Both collection and 
preservation methods were compatible with the downstream applications.
Cell culture. SupT1-CCR5 cells and PBMCs were maintained in RPMI 1640 with L-glutamine (supplemented 
with 10% Foetal Calf Serum (FCS). SupT1-CCR5 cells were split 1:10 twice a week and media was refreshed in 
PBMCs cultures according to the pH indicator of the medium and depended on cell density.
PBMC isolation. PBMCs were isolated from whole blood by density gradient centrifugation using 
Lymphoprep (Alere Technologies AS, Oslo, Norway). Anticoagulated blood was diluted 1:1 with PBS and mixed 
thoroughly. The blood:PBS mixture was layered (up to 34 ml/tube) on top of 15 ml Lymphoprep in a Sepmate-50 
tube (StemCell Technologies, Grenoble, France). Tubes were centrifuged for 10 minutes at 1200 g, with the brake 
on. The lymphocyte containing layer was decanted in new 50 ml tubes and centrifuged for 5 minutes at 900 g to 
pellet the cells. Cells were resuspended and washed twice with PBS.
Purification of resting CD4+ T cells. PBMCs were resuspended in Recommended Medium (RM; 
PBS + 2% FCS + 1 mM EDTA).
Two-step protocol. CD4+ T cells were purified by negative selection using the EasySep Human CD4+ T Cell 
Enrichment Kit (StemCell Technologies) following the manufacturer’s protocol. Resting CD4+ T cells were 
obtained by staining activated cells using anti-human CD25-FITC, CD69-FITC and HLA-DR-FITC and sub-
sequent depletion using the EasySep Human FITC Positive Selection Kit (StemCell Technologies). Purity of the 
obtained resting CD4+ T cells was assessed by flow cytometry using antibodies specific for CD3-PerCp/Cy5, 
CD4-FITC, CD8-Pacific Blue, CD25-Pe/Cy7, CD69-Pacific Blue and HLA-DR-APC.
One-step purification using a custom antibody cocktail. Resting CD4+ T cells were purified using a custom anti-
body cocktail (StemCell Technologies) which consisted of the EasySep Human CD4+ T Cell Enrichment Kit 
supplemented with anti-CD25/CD69/HLA-DR. A change was made to the manufacturer’s protocol to increase 
recovery. Briefly, cells were resuspended at a concentration of 5 × 107 cells/ml in RM in a 14 ml 17 × 100 mm tube 
and custom antibody cocktail was added at 50 μ l/ml, mixed and incubated for 15 minutes at room temperature. 
RapidSpheres were added at 75 μ l/ml, mixed and incubated for 5 minutes at room temperature. The cell suspen-
sion was brought to a total volume of 5 ml (for < 2 × 108 cells) or 10 ml (for > 2 × 108 cells) with RM and mix by 
pipetting up and down and placed in the magnet (‘The Big Easy’ EasySep magnet, StemCell Technologies) for 
5 minutes. The unbound fraction was decanted into a new tube and the RapidSpheres were resuspended in 5 ml 
RM and placed in the magnet again for 5 minutes and decanted in the same tube. The second fraction occasionally 
contained magnetic bead contamination and therefore the combined fraction was placed in the magnet again for 
5 minutes and decanted in a new tube to obtain highly purified resting CD4+ T cells. PBMC isolation and analysis 
by flow cytometry were identical to the two-step protocol.
Limiting dilution assay. Purified resting CD4+ T cells were cultured in 10 ml RPMI medium containing 
10% FCS supplemented with 20 nM efavirenz and 100 nM raltegravir for 2 to 4 days to allow for the degradation 
of unintegrated viral DNA. On ‘day 1’ of the assay, cells were washed thoroughly to remove any traces of antiret-
rovirals and subsequently 5-fold dilutions of resting CD4+ T cells were prepared and stimulated with a 10-fold 
excess of ɣ -irradiated (5000 rad) allogeneic PBMCs and 2 μ g/ml PHA-L and plated in the following manner: 6 
wells with 2.5 × 106 resting CD4+ T cells/well in a 6 well plate, 12 wells with 0.5 × 106 resting CD4+ T cells/well 
in a 12 well plate and 12 wells with 0.1 × 106 resting CD4+ T cells/well in another 12 well plate. Throughout the 
assay cells were maintained in RPMI medium containing 10% FCS supplemented with 10 U/ml IL-2. On day 2, 
24 hours after stimulation all supernatant was carefully aspirated from the cells to remove the PHA and incu-
bated for 2 hours in RPMI medium containing FCS and IL-2. After 2 hours the supernatant was aspirated again 
and SupT1-CCR5 cells were added in fresh media. 6 well plates received 6 ml media containing a total of 1 × 106 
SupT1-CCR5 cells per well and 12 well plates received 3 ml media containing a total of 0.5 × 106 SupT1-CCR5 
cells per well. Half of the media was refreshed on days 9, 12, 16 and 19 and experiments were terminated on day 
23. Supernatants were harvested at several time-points and analysed for HIV-1 p24 production by ELISA.
To compare the SupT1-CCR5 co-culture assay with the standard PBMC co-culture assay, CD8-depleted 
HIV negative donor PBMCs were prepared 48–72 hours before adding the target cells on day 2. In short, 
apheresis cones were obtained from the NHS Blood and Transplant Centre and leukocytes were obtained by 
density-gradient centrifugation. CD8+ T cells were depleted using CD8 Microbeads (Miltenyi, Bisley, UK). A 
portion of CD8-depleted PBMCs was subsequently viably frozen and the remainder was stimulated with 10 U/
ml IL-2 and 2 μ g/ml PHA-L for 48–72 hours. On day 2 of the assay they were washed to remove all mitogens and 
added to the serial dilutions of stimulated CD4+ T cells: 6 well plates received 4 × 106 CD8-depleted PBMCs per 
well and 12 well plates received 1.34 × 106 CD8-depleted PBMCs per well in 6 and 3 ml media respectively. The 
frozen CD8-depleted PBMCs were thawed in two batches on days 7 and 14 and stimulated as described before 
and added to the cultures in a similar fashion on days 9 and 16.
Comparing viral replication efficiency in SupT1-CCR5 cells with HIV negative donor 
PBMCs. Laboratory strain virus stocks (LAI and BaL) were prepared by transfecting 293 T cells with the rel-
evant plasmids and harvesting cell-free supernatant after 48 hours. MCV was a clinical HIV strain isolated from 
patient P16 and cultured in SupT1-CCR5 cells to create a high titre virus stock. The created virus stock appeared 
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to be clonal in the V3 region as determined by Sanger sequencing and had a CCR5 co-receptor usage as pre-
dicted by the Geno2pheno algorithm (http://coreceptor.geno2pheno.org/) with a false positive rate (FPR) of 3.8% 
(cut-off 2.5%). CCR5 co-receptor usage was confirmed by replication experiments in U87.CD4.CXCR4 and U87.
CD4.CCR5 cells (data not shown). Viral titres were determined by adding serial dilutions of virus to TZM-bl cells 
and measuring luciferase activity after 48 hours.
PBMCs from HIV negative donors were obtained as described above. 2 × 108 PBMCs where infected with an 
equivalent infectious dose with either lab strain LAI (X4-tropic virus), BaL (R5-tropic) or clinical isolate MCV 
(R5-tropic) and cultured for 4 days in the presence of 1 μ g/ml PHA-L and 10 U/ml IL-2. In addition to the infected 
PBMCs, 5 × 108 uninfected PBMCs from the same donor were cultured in similar conditions. After 4 days the 
total CD4+ T cells were purified from the cultures using the EasySep Human CD4+ T Cell Enrichment Kit. Serial 
dilutions of infected cells were made in a 12 well plate consisting of 500000, 100000, 50000, 10000, 5000, 1000, 
500, 100, 50, 10, 5 or 1 infected cells per well. Uninfected CD4+ T cells were added to a total of 500000 CD4+ T 
cells in all wells. To mimic assay conditions, these cells were then stimulated with a 10-fold excess of ɣ -irradiated 
allogeneic PBMCs and 2 μ g/ml PHA-L. After 24 hours cells were washed and the amplifier cells were added, either 
0.5 × 106 SupT1-CCR5 cells or 1.34 × 106 PHA-stimulated CD8-depleted donor PBMCs per well. CD8-depleted 
PBMCs from three different unselected seronegative donors were tested as amplifier cells. Co-cultures were main-
tained for 21 days. In the PBMC co-cultures, stimulated CD8-depleted PBMCs (from the same donor) were 
added on days 2, 9 and 16 as opposed to a single addition of SupT1-CCR5 cells on day 2, similar to the assay con-
ditions. Supernatants were harvested at various time-points to analyse HIV-1 p24 production by ELISA.
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